Abridge Stock Price, Valuation & IPO
Last updated on 8 October 2026Abridge is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Source: AXEVIL investment team
Track Abridge Stock Price
We monitor the Abridge stock price based on the latest private market data and funding rounds. Since there is no Abridge stock symbol on public exchanges yet, we provide a consensus price to help you track your investment.
Abridge
Abridge — an AI platform that listens to a doctor-patient conversation and turns it into a ready medical record, billing codes, and prescriptions (№1 according to KLAS, 30% market share). Revenue $60M (2024) → $170M+ (2025), forecast $350–400M in 2026; operates in 250+ US healthcare systems (Kaiser Permanente, Mayo Clinic), in 2026 will process ~100 million conversations. Investors — a16z, Khosla, NVIDIA, CVS Health. IPO target — H2 2027 at a valuation of $16 billion.
Key Metrics Dynamic
See the performance of Abridge's key metrics, based on real market data.
Funding rounds
Key highlights
Where Abridge stands today across technology, financials and market traction.
Best in KLAS Ambient AI 2025 + 2026 — #1 among users.
Even with Microsoft/Nuance holding 33% of the market, it is Abridge that leads in satisfaction, which in healthcare means long-term contracts.
Epic "First Pal" is the only one with deep Epic integration.
Epic in 42% of USA hospitals; Abridge is the only official partner of the program, retaining the privilege even after the launch of Epic AI Charting.
Re-acceleration of contracts: 110 → 250 health systems in 12 months.
Kaiser, Northwell, UPMC are moving from pilots to full implementations; ARR forecast 2026 $350–400M (+~120%), by H2 2027 ~$700M.
Content moat: NEJM + JAMA + UpToDate.
Exclusive partnerships with three main sources of medical knowledge (April 2026) transform scribe into a full-fledged clinical assistant.
Proven clinical effect.
−67% physician burnout (JAMIA), −59% cognitive load, and −28% time spent on documentation — mitigates regulatory risks and unlocks CMO/CMIO budgets.
News
Frequently Asked Questions
Not on a public exchange — Abridge is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
A private company has no single official share price. AXEVIL's consensus estimate is $194.38 per share as of 18 June 2025. Its most recent round implied a post-money valuation of $5.3B (June 2025).
Abridge's most recent funding round valued the company at $5.3B post-money (June 2025) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
No. Abridge is a private company and its shares are not listed on any public exchange.
No. Abridge has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Get Updates
Stay informed about Abridge stock news and new investment rounds.
Risk disclosure and data sources
Secondary-market prices and investment round data on this page, current and historical, are based on publicly available information and on data from market participants, and are provided for informational purposes only. Axevil Capital strives for accuracy; all prices and valuations are approximate and may fluctuate significantly due to low liquidity and limited access to information. The secondary market for private company shares is illiquid and does not guarantee the ability to buy or sell shares at the displayed price.
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.
Axevil Capital, LLC is a Delaware limited liability company (registration No. 6832739) operating as an investment adviser relying on an exemption from registration, filed with the SEC as an Exempt Reporting Adviser (SEC file No. 802-126907; CRD No. 323970). ERA status means the Company files reports with the SEC but is not a registered investment adviser. The Company is not a broker-dealer and is not a member of FINRA or SIPC.